Twist Bioscience Co. (NASDAQ:TWST) Given Average Rating of "Buy" by Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has been given a consensus recommendation of "Buy" by the six brokerages that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $41.67.

Several brokerages have issued reports on TWST. Scotiabank boosted their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a "sector outperform" rating in a research note on Monday, February 5th. The Goldman Sachs Group upgraded shares of Twist Bioscience from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Evercore ISI upped their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday. Robert W. Baird upped their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday. Finally, Barclays upped their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Friday.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded up $9.20 during trading on Friday, hitting $41.21. The company had a trading volume of 4,457,624 shares, compared to its average volume of 975,484. The company has a market cap of $2.38 billion, a P/E ratio of -11.25 and a beta of 1.64. Twist Bioscience has a 52 week low of $11.81 and a 52 week high of $43.21. The business's 50-day moving average is $33.97 and its 200 day moving average is $30.79.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same period in the previous year, the business earned ($1.06) EPS. The company's revenue was up 25.1% on a year-over-year basis. On average, research analysts expect that Twist Bioscience will post -3.17 EPS for the current year.

Insider Buying and Selling

In other news, COO Patrick John Finn sold 2,174 shares of the firm's stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the sale, the chief operating officer now owns 176,206 shares of the company's stock, valued at $5,307,324.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Robert Chess sold 4,110 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares of the company's stock, valued at $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Patrick John Finn sold 2,174 shares of the firm's stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the transaction, the chief operating officer now directly owns 176,206 shares in the company, valued at $5,307,324.72. The disclosure for this sale can be found here. Insiders sold 13,211 shares of company stock valued at $449,573 over the last quarter. Corporate insiders own 3.92% of the company's stock.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the company. Jennison Associates LLC increased its stake in Twist Bioscience by 523.1% during the 1st quarter. Jennison Associates LLC now owns 150,022 shares of the company's stock worth $5,147,000 after purchasing an additional 125,946 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Twist Bioscience by 34.8% in the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company's stock valued at $5,895,000 after buying an additional 44,349 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Twist Bioscience by 30.7% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 156,288 shares of the company's stock worth $5,362,000 after acquiring an additional 36,744 shares in the last quarter. Baillie Gifford & Co. raised its holdings in shares of Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock worth $42,116,000 after acquiring an additional 132,770 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Twist Bioscience by 151.2% in the 1st quarter. Principal Financial Group Inc. now owns 39,624 shares of the company's stock valued at $1,360,000 after acquiring an additional 23,850 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.